NCT04322578 (CONFIRM) is a Phase 2 clinical trial of Crizotinib in Non-small Cell Lung Cancer, sponsored by Hunan Province Tumor Hospital.

Who is sponsoring NCT04322578?

NCT04322578 is sponsored by Hunan Province Tumor Hospital.

What drugs are being tested in NCT04322578?

Interventions in NCT04322578: Crizotinib, Pemetrexed.

What condition does NCT04322578 study?

NCT04322578 studies Non-small Cell Lung Cancer.

Is NCT04322578 still recruiting?

NCT04322578 is currently recruiting now. Last updated 4 June 2024.

Last reviewed 2024-06-04 · How we verify

NCT04322578: CONFIRM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Recruiting now Phase 2 Last updated 4 June 2024

What this trial tests

Phase 2 trial testing Crizotinib in Non-small Cell Lung Cancer in 120 participants. Currently enrolling.

Timeline

24 March 2020

Primary endpoint
24 March 2025

24 March 2026

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	24 March 2020
Primary completion	24 March 2025
Estimated completion	24 March 2026
Sites	1 location across China

Drugs / interventions tested

Crizotinib (crizotinib) — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Hunan Province Tumor Hospital

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.
Zhang D, Zhang W, Liu H, Liu P, et al · · 2024 · cited 1× · PMID 39720556 · DOI 10.3389/fchem.2024.1501844
Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.
Wang X, Chi Y, Mu F, Mao H, et al · · 2026 · PMID 41981677 · DOI 10.1186/s12967-026-08077-2

Verify or expand the search:

Other trials of Crizotinib

Trials testing the same drug.

NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting
NCT06140836 — A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor · Phase 3 · active not recruiting
NCT06082635 — TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) · Phase 3 · active not recruiting
NCT05987332 — IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · Phase 2, PHASE3 · active not recruiting
NCT05725200 — Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · Phase 2 · recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04322578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 4 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing